CTI BioPharma, Shire deal

CTI said Shire terminated a 2013 license agreement and returned exclusive, worldwide rights to develop and commercialize myelofibrosis candidate pacritinib ( BAX 2201). Shire gained rights to the candidate via its acquisition of Baxalta Inc., which had obtained rights from CTI. ...